Source label information, not individualized medical advice. This record applies to the product and labeler shown below. Compare the exact formulation, strength and country with your package and the current source label.
Generic nameEPINEPHRINE
Labeler / manufacturerAmneal Pharmaceuticals of New York LLC
RouteSUBCUTANEOUS
Drug classalpha-Adrenergic Agonist / beta-Adrenergic Agonist / Catecholamine
Product NDC0115-1694, 0115-1695
Label effective date2026-03-20
Official product label reference
epinephrine — Amneal Pharmaceuticals of New York LLC
This page contains 22 source sections for EPINEPHRINE, subcutaneous route. Label set e13f05f1-7d21-49bb-b8d5-24bf9301c3d7, version 16.
Label records can cover multiple strengths or package sizes. A label listing does not by itself establish FDA approval or current market availability. Check the source and application history for this specific product.
Uses described in the label
1 INDICATIONS AND USAGE Epinephrine Injection is indicated for the emergency treatment of type I allergic reactions, including anaphylaxis in adult and pediatric patients who weigh 15 kg or greater. Epinephrine Injection is a alpha and beta-adrenergic receptor agonist, indicated for the emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 15 kg or greater. ( 1 )
Dosage and administration — label text
2 DOSAGE AND ADMINISTRATION The recommended dosage of Epinephrine Injection is based on weight. (2.1) Administer Epinephrine Injection intramuscularly or subcutaneously into the anterolateral aspect of the thigh, through clothing if necessary. (2.2) Recommended Dosage Patient’s Weight Dosage 30 kg or greater 0.3 mg 15 kg to less than 30 kg 0.15 mg In the absence of clinical improvement or if symptoms worsen after the initial treatment, a second dose of Epinephrine Injection may be administered with a second auto-injector starting 5 minutes after the first dose. (2.1) Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required. (2.1) It is recommended that patients are prescribed and have immediate access to two Epinephrine Injection devices at all times. (2.1) See full prescribing information for administration instructions. (2.2) 2.1 Recommended Dosage Recommended dosage for patients who weigh 15 kg or greater is based on weight and the dosage is provided in Table 1. Administer Epinephrine Injection intramuscularly or subcutaneously into the anterolateral aspect of the thigh. Table 1 Recommended Dosage of Epinephrine Injection Based on Patient’s Weight Patient’s Weight Dosage 30 kg or greater 0.3 mg 15 kg to less than 30 kg 0.15 mg Since the doses of epinephrine delivered from Epinephrine Injection are fixed, use other forms of injectable epinephrine if doses lower than 0.15 mg are deemed necessary. In the absence of clinical improvement or if symptoms worsen after the initial treatment, a second dose of Epinephrine Injection may be administered with a second auto-injector starting 5 minutes after the first dose. Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required. It is recommended that patients are prescribed and have immediate access to two Epinephrine Injection devices at all times. 2.2 Administration Instructions Injection: 0.3 mg (0.3 mg/0.3 mL) of clear and colorless solution in single-dose pre-filled auto-injector 0.15 mg (0.15 mg/0.15 mL) of clear and colorless solution in single-dose pre-filled auto-injector
Table text from source:
| Patient’s Weight | Dosage
| 30 kg or greater | 0.3 mg
| 15 kg to less than 30 kg | 0.15 mg
| Patient’s Weight | Dosage
| 30 kg or greater | 0.3 mg
| 15 kg to less than 30 kg | 0.15 mg
Forms and strengths
3 DOSAGE FORMS AND STRENGTHS Injection: 0.3 mg (0.3 mg/0.3 mL) of clear and colorless solution in single-dose pre-filled auto-injector Injection: 0.15 mg (0.15 mg/0.15 mL) of clear and colorless solution in single-dose pre-filled auto-injector Injection: 0.3 mg (0.3 mg/0.3 mL) single-dose pre-filled auto-injector (3) 0.15 mg (0.15 mg/0.15 mL) single-dose pre-filled auto-injector (3)
Contraindications
4 CONTRAINDICATIONS None. None. ( 4 )
Warnings and precautions
5 WARNINGS AND PRECAUTIONS Do not inject intravenously, into buttock, or into digits, hands, or feet. (5.1) Hold the child’s leg firmly in place and limit movement prior to and during injection when administering to young children or infants to minimize the risk of injection-related injury. (5.1) Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop signs or symptoms of infection. (5.2) Administer with caution in patients with heart disease; may aggravate angina pectoris or produce ventricular arrhythmias. (5.3) May aggravate certain coexisting conditions. (5.3) The presence of a sulfite in this product should not deter use. (5.4) 5.1 Injection-Related Complications Epinephrine Injection should only be injected into the anterolateral aspect of the thigh [see Dosage and Administration (2.2) ] . Do not inject intravenously Large doses or accidental intravenous injection of epinephrine may result in cerebral hemorrhage due to a sharp rise in blood pressure. Rapidly acting vasodilators can counteract the marked pressor effects of epinephrine for this inadvertent administration. Do not inject into buttock Injection into the buttock may not provide effective treatment of anaphylaxis. If Epinephrine Injection is injected into the buttock, advise the patient to administer a second dose of Epinephrine Injection into the anterolateral aspect of the thigh if symptoms worsen or persist, and then go immediately to the nearest emergency room for further treatment of anaphylaxis. Additionally, injection into the buttock has been associated with the development of Clostridial infections (gas gangrene). Cleansing with alcohol does not kill bacterial spores, and therefore, does not lower the risk. Do not inject into digits, hands or feet Since epinephrine is a strong vasoconstrictor, accidental injection into the digits, hands or feet may result in loss of blood flow to the affected area and may not provide effective treatment of anaphylaxis. Advise the patient to administer a second dose of Epinephrine Injection into the anterolateral aspect of the thigh if experiencing anaphylaxis, and then go immediately to the nearest emergency room and inform the healthcare provider in the emergency room of the location of the accidental injection. Treatment of such inadvertent administration should consist of vasodilation, in addition to further appropriate treatment of anaphylaxis [see Adverse Reactions (6)] . Hold leg firmly during injection To minimize the risk of injection related injury when administering Epinephrine Injection to young children or infants, instruct caregivers to hold the child’s leg firmly in place and limit movement prior to and during injection. 5.2 Serious Infections at the Injection Site Rare cases of serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported at the injection site following epinephrine injection for anaphylaxis. Clostridium spores can be present on the skin and introduced into the deep tissue with subcutaneous or intramuscular injection. While cleansing with alcohol may reduce presence of bacteria on the skin, alcohol cleansing does not kill Clostridium spores. To decrease the risk of Clostridium infection, do not inject Epinephrine Injection into the buttock [see Warnings and Precautions (5.1) ] . Advise patients to seek medical care if they develop signs or symptoms of infection, such as persistent redness, warmth, swelling, or tenderness, at the epinephrine injection site. 5.3 Risks Associated with Use of Epinephrine in Certain Coexisting Conditions Some patients may be at greater risk for developing adverse reactions after epinephrine administration. Despite these concerns, it should be recognized that the presence of these conditions is not a contraindication to epinephrine administration in an acute, life-threatening situation. Therefore, instruct patients with these conditions, and/or caregivers to the circumstances under which epinephrine should be used. Administer epinephrine with caution to patients who have heart disease, including patients with cardiac arrhythmias, coronary artery or organic heart disease, or hypertension. In such patients, or in patients who are on drugs that may sensitize the heart to arrhythmias, epinephrine may precipitate or aggravate angina pectoris as well as produce ventricular arrhythmias [see Adverse Reactions (6) and Drug Interactions (7) ] . Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in patients with the following: hyperthyroidism, Parkinson’s disease, diabetes, renal impairment. Administer epinephrine with caution in patients with these conditions, including elderly patients and pregnant women. 5.4 Allergic Reactions Associated with Sulfite Epinephrine is the preferred treatment for serious allergic reactions or other emergency situations even though Epinephrine Injection contains sodium bisulfite, a sulfite that may, in other products, cause allergic-type reactions including anaphylactic symptoms or life-threatening or less severe asthmatic episodes in certain susceptible persons. The alternatives to using epinephrine in a life-threatening situation may not be satisfactory. The presence of a sulfite in Epinephrine Injection should not deter administration of the drug for treatment of serious allergic or other emergency situations.
Adverse reactions
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Injection-Related Complications [see Warnings and Precautions (5.1) ] Serious Infections at the Injections [see Warnings and Precautions (5.2) ] Risks Associated with Use of Epinephrine in Certain Coexisting Conditions [see Warnings and Precautions (5.3) ] Allergic Reactions Associated with Sulfite [see Warnings and Precautions (5.4) ] The following adverse reactions associated with the use of epinephrine were identified in observational trials, case reports, studies, or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiovascular : angina, arrhythmias (including fatal ventricular fibrillation), cerebral hemorrhage, hypertension, pallor, palpitations, tachyarrhythmia, tachycardia, vasoconstriction, ventricular ectopy, and stress cardiomyopathy Gastrointestinal Disorders : nausea and vomiting Infections : Clostridial infections (gas gangrene) Metabolism and Nutrition Disorders : transient hyperglycemia, sweating Neurological: disorientation, impaired memory, panic, psychomotor agitation, sleepiness, tingling, weakness, tremor, hypoesthesia, dizziness, headache Psychiatric : anxiety, apprehensiveness, restlessness Respiratory : respiratory difficulties Skin and Subcutaneous Tissue Disorders: bruising, bleeding, discoloration, erythema, necrotizing fasciitis, myonecrosis Adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties. (6) To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Drug interactions
7 DRUG INTERACTIONS Cardiac glycosides, diuretics, or anti-arrhythmics: observe for development of cardiac arrhythmias. (7.1) Tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, certain antihistamines, and catechol-O-methyl transferase inhibitors: may potentiate effects of epinephrine. (7.2) Beta-adrenergic blocking drugs: antagonize cardiostimulating and bronchodilating effects of epinephrine. (7.3) Alpha-adrenergic blocking drugs: antagonize vasoconstricting and hypertensive effects of epinephrine. (7.3) Ergot alkaloids: may reverse the pressor effects of epinephrine. (7.3) 7.1 Drugs Increasing Risk of Cardiac Arrhythmias Patients who receive epinephrine while concomitantly taking cardiac glycosides, diuretics, or anti-arrhythmics should be observed carefully for the development of cardiac arrhythmias [see Warnings and Precautions (5.3) and Adverse Reactions (6) ] . 7.2 Drugs Potentiating Effects of Epinephrine The effects of epinephrine may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine, and catechol-O-methyl transferase (COMT) inhibitors such as entacapone. 7.3 Drugs Antagonizing Effects of Epinephrine The cardiostimulating and bronchodilating effects of epinephrine are antagonized by beta- adrenergic blocking drugs, such as propranolol. The vasoconstricting and hypertensive effects of epinephrine are antagonized by alpha-adrenergic blocking drugs, such as phentolamine. Ergot alkaloids may also reverse the pressor effects of epinephrine.
Special populations
8 USE IN SPECIFIC POPULATIONS Elderly patients may be at greater risk of developing adverse reactions. (5.3 , 8.5) 8.1 Pregnancy Risk Summary Prolonged experience with epinephrine use in pregnant women over several decades, based on published literature, have not identified a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with anaphylaxis, and treatment with epinephrine should not be delayed (see Clinical Considerations) . In animal reproduction studies, epinephrine administered by the subcutaneous route to pregnant rabbits, mice, and hamsters, during the period of organogenesis was teratogenic at doses 7 times and higher than the maximum recommended human intramuscular and subcutaneous dose on a mg/m 2 basis (see Data). The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-Associated Maternal and Embryo/Fetal Risk: During pregnancy, anaphylaxis can be catastrophic and can lead to hypoxic-ischemic encephalopathy and permanent central nervous system damage or death in the mother and, more commonly, in the fetus or neonate. Treatment of anaphylaxis during pregnancy should not be delayed. Data Animal Data In an embryofetal development study with rabbits dosed during the period of organogenesis, epinephrine was shown to be teratogenic (including gastroschisis and embryonic lethality) at doses approximately 40 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2 basis at a maternal subcutaneous dose of 1.2 mg/kg/day for two to three days). In an embryofetal development study with mice dosed during the period of organogenesis, epinephrine was shown to be teratogenic (including embryonic lethality) at doses approximately 8 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2 basis at maternal subcutaneous dose of 1 mg/kg/day for 10 days). These effects were not seen in mice at approximately 4 times the maximum recommended daily intramuscular or subcutaneous dose (on a mg/m 2 basis at a subcutaneous maternal dose of 0.5 mg/kg/day for 10 days). In an embryofetal development study with hamsters dosed during the period of organogenesis from gestation days 7 to 10, epinephrine was shown to be teratogenic at doses approximately 7 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2 basis at a maternal subcutaneous dose of 0.5 mg/kg/day). 8.2 Lactation Risk Summary There is no information on the presence of epinephrine in human milk, the effects on the breastfed infants, or the effects on milk production. However, due to its poor oral bioavailability and short half-life, transfer of epinephrine into breastmilk is expected to be low. Treatment of anaphylaxis in breastfeeding patients should not be delayed. 8.4 Pediatric Use The safety and effectiveness of Epinephrine Injection for the emergency treatment of type I allergic reactions, including anaphylaxis have been established in pediatric patients who weigh 15 kg or greater. The use of Epinephrine Injection for this indication is supported by clinical experience. Clinical experience with the use of epinephrine suggests that the adverse reactions seen in pediatric patients are similar in nature and extent to those both expected and reported in adults. Since the doses of epinephrine delivered from Epinephrine Injection are fixed, use other forms of injectable epinephrine if doses lower than 0.15 mg are deemed necessary. The safety and effectiveness of Epinephrine Injection have not been established in pediatric patients who weigh less than 15 kg. 8.5 Geriatric Use Clinical studies of Epinephrine Injection for emergency treatment of type I allergic reactions, including anaphylaxis, were not conducted in geriatric patients aged 65 and over to determine whether they respond differently from younger adult patients. However, other reported clinical experience with use of epinephrine for the treatment of anaphylaxis has identified that geriatric patients may be particularly sensitive to the effects of epinephrine. Therefore, these patients may be at greater risk for developing adverse reactions after epinephrine administration.
Pregnancy
8.1 Pregnancy Risk Summary Prolonged experience with epinephrine use in pregnant women over several decades, based on published literature, have not identified a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with anaphylaxis, and treatment with epinephrine should not be delayed (see Clinical Considerations) . In animal reproduction studies, epinephrine administered by the subcutaneous route to pregnant rabbits, mice, and hamsters, during the period of organogenesis was teratogenic at doses 7 times and higher than the maximum recommended human intramuscular and subcutaneous dose on a mg/m 2 basis (see Data). The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-Associated Maternal and Embryo/Fetal Risk: During pregnancy, anaphylaxis can be catastrophic and can lead to hypoxic-ischemic encephalopathy and permanent central nervous system damage or death in the mother and, more commonly, in the fetus or neonate. Treatment of anaphylaxis during pregnancy should not be delayed. Data Animal Data In an embryofetal development study with rabbits dosed during the period of organogenesis, epinephrine was shown to be teratogenic (including gastroschisis and embryonic lethality) at doses approximately 40 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2 basis at a maternal subcutaneous dose of 1.2 mg/kg/day for two to three days). In an embryofetal development study with mice dosed during the period of organogenesis, epinephrine was shown to be teratogenic (including embryonic lethality) at doses approximately 8 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2 basis at maternal subcutaneous dose of 1 mg/kg/day for 10 days). These effects were not seen in mice at approximately 4 times the maximum recommended daily intramuscular or subcutaneous dose (on a mg/m 2 basis at a subcutaneous maternal dose of 0.5 mg/kg/day for 10 days). In an embryofetal development study with hamsters dosed during the period of organogenesis from gestation days 7 to 10, epinephrine was shown to be teratogenic at doses approximately 7 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2 basis at a maternal subcutaneous dose of 0.5 mg/kg/day).
Children and adolescents
8.4 Pediatric Use The safety and effectiveness of Epinephrine Injection for the emergency treatment of type I allergic reactions, including anaphylaxis have been established in pediatric patients who weigh 15 kg or greater. The use of Epinephrine Injection for this indication is supported by clinical experience. Clinical experience with the use of epinephrine suggests that the adverse reactions seen in pediatric patients are similar in nature and extent to those both expected and reported in adults. Since the doses of epinephrine delivered from Epinephrine Injection are fixed, use other forms of injectable epinephrine if doses lower than 0.15 mg are deemed necessary. The safety and effectiveness of Epinephrine Injection have not been established in pediatric patients who weigh less than 15 kg.
Older adults
8.5 Geriatric Use Clinical studies of Epinephrine Injection for emergency treatment of type I allergic reactions, including anaphylaxis, were not conducted in geriatric patients aged 65 and over to determine whether they respond differently from younger adult patients. However, other reported clinical experience with use of epinephrine for the treatment of anaphylaxis has identified that geriatric patients may be particularly sensitive to the effects of epinephrine. Therefore, these patients may be at greater risk for developing adverse reactions after epinephrine administration.
Overdose information
10 OVERDOSAGE Overdosage of epinephrine has been reported to produce extremely elevated arterial pressure, which may result in cerebrovascular hemorrhage, particularly in elderly patients. Overdosage may also result in pulmonary edema because of peripheral vascular constriction together with cardiac stimulation. Epinephrine overdosage can also cause transient bradycardia followed by tachycardia which may be accompanied by fatal cardiac arrhythmias; premature ventricular contractions followed by multifocal ventricular tachycardia; atrial tachycardia and occasionally by atrioventricular block; extreme pallor and coldness of the skin; metabolic acidosis; kidney failure. Epinephrine is rapidly inactivated in the body and treatment following overdosage with epinephrine is primarily supportive. Treatment of epinephrine associated pulmonary edema consists of a rapidly acting alpha-adrenergic blocking drug (such as phentolamine mesylate) and respiratory support. Treatment of epinephrine associated arrhythmias consists of administration of a beta-adrenergic blocking drug (such as propranolol). If necessary, pressor effects may be counteracted by rapidly acting vasodilators or α-adrenergic blocking drugs. If prolonged hypotension follows such measures, it may be necessary to administer another pressor drug. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.
Product description
11 DESCRIPTION Epinephrine Injection, USP 0.3 mg and 0.15 mg, are single-dose auto-injectors and combination products containing drug and device components. Each Epinephrine Injection, USP 0.3 mg, delivers a single dose of 0.3 mg epinephrine from Epinephrine Injection, USP (0.3 mL) in a sterile solution. Each Epinephrine Injection, USP 0.15 mg, delivers a single dose of 0.15 mg epinephrine from Epinephrine Injection, USP (0.15 mL) in a sterile solution. Epinephrine Injection, USP 0.3 mg and Epinephrine Injection, USP 0.15 mg each contain 1.1 mL of epinephrine solution. 0.3 mL and 0.15 mL epinephrine solution are dispensed for Epinephrine Injection, USP 0.3 mg and Epinephrine Injection, USP 0.15 mg, respectively, when activated. The solution remaining after activation is not available for future use and should be discarded. Each 0.3 mL in Epinephrine Injection, USP 0.3 mg, contains 0.3 mg epinephrine, 2.6 mg sodium chloride, not more than 1.5 mg chlorobutanol, 0.45 mg sodium bisulfite, hydrochloric acid and sodium hydroxide to adjust pH, and water for injection. The pH range is 2.2-5.0. Each 0.15 mL in Epinephrine Injection, USP 0.15 mg, contains 0.15 mg epinephrine, 1.3 mg sodium chloride, not more than 0.75 mg chlorobutanol, 0.225 mg sodium bisulfite, hydrochloric acid and sodium hydroxide to adjust pH, and water for injection. The pH range is 2.2-5.0. Epinephrine is a sympathomimetic catecholamine. Chemically, epinephrine is (-)-3,4-Dihydroxy-α-[(methylamino)methyl]benzyl alcohol with the following structure: Epinephrine solution deteriorates rapidly on exposure to air or light, turning pink from oxidation to adrenochrome and brown from the formation of melanin. Replace Epinephrine Injection, USP if the epinephrine solution appears discolored (pinkish or brown color), cloudy, or contains particles. Chemical Structure
Clinical pharmacology
12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Epinephrine acts on both alpha- and beta-adrenergic receptors. Through its action on alpha-adrenergic receptors, epinephrine lessens the vasodilation and increased vascular permeability that occurs during anaphylaxis, which can lead to loss of intravascular fluid volume and hypotension. Through its action on beta-adrenergic receptors, epinephrine causes bronchial smooth muscle relaxation and helps alleviate bronchospasm, wheezing, and dyspnea that may occur during anaphylaxis. Epinephrine also alleviates pruritus, urticaria, and angioedema, and may relieve gastrointestinal and genitourinary symptoms associated with anaphylaxis because of its relaxer effects on the smooth muscle of the stomach, intestine, uterus and urinary bladder. 12.2 Pharmacodynamics When given subcutaneously or intramuscularly, epinephrine has a rapid onset and short duration of action.
How it works
12.1 Mechanism of Action Epinephrine acts on both alpha- and beta-adrenergic receptors. Through its action on alpha-adrenergic receptors, epinephrine lessens the vasodilation and increased vascular permeability that occurs during anaphylaxis, which can lead to loss of intravascular fluid volume and hypotension. Through its action on beta-adrenergic receptors, epinephrine causes bronchial smooth muscle relaxation and helps alleviate bronchospasm, wheezing, and dyspnea that may occur during anaphylaxis. Epinephrine also alleviates pruritus, urticaria, and angioedema, and may relieve gastrointestinal and genitourinary symptoms associated with anaphylaxis because of its relaxer effects on the smooth muscle of the stomach, intestine, uterus and urinary bladder.
Pharmacodynamics
12.2 Pharmacodynamics When given subcutaneously or intramuscularly, epinephrine has a rapid onset and short duration of action.
Nonclinical toxicology
13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies to evaluate the carcinogenic potential of epinephrine have not been conducted. Epinephrine and other catecholamines have been shown to have mutagenic potential in vitro . Epinephrine was positive in the Salmonella bacterial reverse mutation assay, positive in the mouse lymphoma assay, and negative in the in vivo micronucleus assay. Epinephrine is an oxidative mutagen based on the E. coli WP2 Mutoxitest bacterial reverse mutation assay. This should not prevent the use of epinephrine where indicated [see Indications and Usage (1) ] . The potential for epinephrine to impair reproductive performance has not been evaluated, but epinephrine has been shown to decrease implantation in female rabbits dosed subcutaneously with 1.2 mg/kg/day (40-fold the highest human intramuscular or subcutaneous daily dose) during gestation days 3 to 9.
Carcinogenesis and mutagenesis and impairment of fertility
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies to evaluate the carcinogenic potential of epinephrine have not been conducted. Epinephrine and other catecholamines have been shown to have mutagenic potential in vitro . Epinephrine was positive in the Salmonella bacterial reverse mutation assay, positive in the mouse lymphoma assay, and negative in the in vivo micronucleus assay. Epinephrine is an oxidative mutagen based on the E. coli WP2 Mutoxitest bacterial reverse mutation assay. This should not prevent the use of epinephrine where indicated [see Indications and Usage (1) ] . The potential for epinephrine to impair reproductive performance has not been evaluated, but epinephrine has been shown to decrease implantation in female rabbits dosed subcutaneously with 1.2 mg/kg/day (40-fold the highest human intramuscular or subcutaneous daily dose) during gestation days 3 to 9.
Supply and packaging
16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied Epinephrine Injection is a clear and colorless solution for intramuscular or subcutaneous use. Epinephrine Injection is available as an auto-injector as described in Table 2. Table 2 Epinephrine Injection Auto-injector Package Configurations and Strengths Strength Package Configuration NDC 0.3 mg/0.3 mL Each carton contains 2 single-dose prefilled auto-injectors in individual carrier tubes NDC 0115-1694-49 Auto-injector in carrier tube NDC 0115-1694-30 0.15 mg/0.15 mL Each carton contains 2 single-dose prefilled auto-injectors in individual carrier tubes NDC 0115-1695-49 Auto-injector in carrier tube NDC 0115-1695-30 Storage and Handling Protect from light. Epinephrine Injection is light sensitive and should be stored in the individual carrier tube provided. Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature]. Do not refrigerate or freeze. Before using, check to make sure the solution in the auto-injector is clear and colorless. Replace the auto-injector if the solution is discolored (pinkish or brown color), cloudy, or contains particles. Properly dispose of all used, unwanted, or expired Epinephrine Injection, USP.
Table text from source:
| Strength | Package Configuration | NDC
| 0.3 mg/0.3 mL | Each carton contains 2 single-dose prefilled auto-injectors in individual carrier tubes | NDC 0115-1694-49
| Auto-injector in carrier tube | NDC 0115-1694-30
| 0.15 mg/0.15 mL | Each carton contains 2 single-dose prefilled auto-injectors in individual carrier tubes | NDC 0115-1695-49
| Auto-injector in carrier tube | NDC 0115-1695-30
PATIENT INFORMATION PATIENT INFORMATION EPINEPHRINE injection (ep″ i nef′ rin), for intramuscular or subcutaneous use Epinephrine Injection USP, 0.3 mg Each Epinephrine Injection USP, 0.3 mg delivers a single dose of 0.3 mg epinephrine USP, in 0.3 mL (0.3 mg/0.3 mL) Epinephrine Injection USP, 0.15 mg Each Epinephrine Injection USP, 0.15 mg delivers a single dose of 0.15 mg epinephrine USP, in 0.15 mL (0.15 mg/0.15 mL) For allergic emergencies (anaphylaxis) Read this Patient Information leaflet carefully before you use Epinephrine Injection and each time you get a refill. There may be new information. You, your parent, caregiver, or others who may be able to administer Epinephrine Injection should know how to use it before you have an allergic emergency. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment. What is the most important information I should know about Epinephrine Injection? 1. Epinephrine Injection is a medicine used to treat allergic emergencies (anaphylaxis). Anaphylaxis can be life-threatening and can happen within minutes. If untreated, anaphylaxis can lead to death. Allergic emergencies may be caused by stinging and biting insects, allergy injections, foods, medicines, exercise, or other unknown causes. Symptoms of anaphylaxis may include: trouble breathing wheezing hoarseness (changes in the way your voicesounds) hives (raised reddened rash that may itch) severe itching swelling of your face, lips, mouth, or tongue skin rash, redness, or swelling fast heartbeat weak pulse feeling very anxious confusion stomach pain losing control of urine or bowel movements (incontinence) diarrhea or stomach cramps dizziness, fainting, or “passing out” (unconsciousness) 2. It is recommended that people are prescribed and have immediate access to 2 Epinephrine Injection devices at all times. Sometimes a single dose of epinephrine may not be enough to treat a serious allergic reaction before seeking emergency medical help. You should also have immediate access to 2 Epinephrine Injection devices in case the first device is activated before the dose can be given. A device that has been activated accidentally cannot be used to treat an allergic emergency (anaphylaxis). Note: Epinephrine Injection has been activated if you see the needle sticking out of the red needle end and the viewing window is blocked. You may not know when an allergic emergency (anaphylaxis) will happen. Talk to your healthcare provider if you need additional Epinephrine Injection devices to keep at work, school, or other locations. If you use 1 Epinephrine Injection device to treat an emergency allergic reaction, be sure to replace it so you always have immediate access to 2 devices. Tell your family members, caregivers, and others where you keep your Epinephrine Injection. Make sure they know how to use it before you need it. You may be unable to speak in an allergic emergency. 3. When you have an allergic emergency (anaphylaxis) use Epinephrine Injection right away. Get emergency medical help for further treatment of the allergic emergency (anaphylaxis), if needed, after using Epinephrine Injection. Before you receive Epinephrine Injection, your healthcare provider should talk to you about when to get emergency help . If symptoms do not improve or if they worsen after the first dose, or you accidentally inject Epinephrine Injection intothe fingers, toes, hands or feet, a second dose of Epinephrine Injection may be administered with a second auto-injector starting 5 minutes after the first dose. If more than 2 doses are needed for an allergic emergency, they must be given by a healthcare provider. What is Epinephrine Injection? Epinephrine Injection is a medicine used to treat life-threatening allergic emergencies (anaphylaxis). It is delivered using a disposable, prefilled automatic injection device (auto-injector). Each auto-injector contains a single dose of epinephrine. Epinephrine Injection is for immediate administration by you or your caregiver. Get emergency medical help, if needed, after using Epinephrine Injection. Your healthcare provider should talk to you about when to get emergency help. Epinephrine Injection is for people who have been prescribed this medicine by their healthcare provider. The Epinephrine Injection 0.3 mg auto-injector is for people who weigh 66 pounds or greater. The Epinephrine Injection 0.15 mg auto-injector is for people who weigh 33 pounds to less than 66 pounds. It is not known if Epinephrine Injection is safe and effective in children who weigh less than 33 pounds. What should I tell my healthcare provider before using Epinephrine Injection? Before you use Epinephrine Injection, tell your healthcare provider about all your medical conditions. Your healthcare provider may give you more instructions about when and how to use your Epinephrine Injection if you have the following: heart problems or high blood pressure diabetes thyroid problems asthma a history of depression Parkinson’s disease kidney (renal) problems You may also receive more instructions if you: are pregnant or plan to become pregnant. It is not known if epinephrine will harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if epinephrine passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Also tell your healthcare provider about all known allergies. Some medicines may increase or decrease the effects of epinephrine, and epinephrine may affect how other medicines work. Know the medicines you take. Keep a list of all your medicines, including over-the-counter medicines, vitamins and herbal supplements to show your healthcare provider and pharmacist when you get a new medicine. Use your Epinephrine Injection for treatment of anaphylaxis as prescribed by your healthcare provider, regardless of your medical conditions or the medicine you take. How should I use Epinephrine Injection? Use your single-dose Epinephrine Injection exactly as your healthcare provider tells you to use it. When you have an allergic emergency (anaphylaxis), use Epinephrine Injection right away. Get emergency medical help, if needed, after using Epinephrine Injection. You may need to use a second Epinephrine Injection if symptoms continue or come back after the first dose. A second dose may be administered starting 5 minutes after the first dose while you wait for emergency medical help, or if the first Epinephrine Injection is activated before the dose can be given. If you need more than 2 doses of epinephrine for a single anaphylaxis episode, additional doses must be given by a healthcare provider. Epinephrine Injection should only be injected into the middle of the outer thigh (upper leg). It can be injected through clothing if needed. Do not inject into a vein, buttocks, fingers, toes, hands or feet. If Epinephrine Injection is injected into the fingers, toes, hands or feet, administer a second dose of Epinephrine Injection into the middle of the outer thigh (upper leg). If symptoms worsen or persist, go immediately to the nearest emergency room for further treatment of anaphylaxis. Read and make sure you understand the Instructions for Use for information about the correct way to use Epinephrine Injection. Your healthcare provider will show you how to safely use Epinephrine Injection. It is very important that you hold Epinephrine Injection firmly against the middle of the outer thigh (upper leg) for a full 10 seconds. If you do not hold it in place long enough, Epinephrine Injection may not deliver the full dose of medicine. Caution: Never put your thumb, fingers, or hand over the red needle end. Never press or push the red needle end with your thumb, fingers, or hand.The needle comes out of the red needle end. Accidental injection into the fingers, hands, or feet may cause a loss of blood flow to those areas. If this happens, give a second dose of Epinephrine Injection into the middle of the outer thigh (upper leg) and go immediately to the nearest emergency room. Tell the healthcare provider where on your body the injection occurred. Warning: After the device is activated, the needle does not retract back into the device. After use, carefully place the used auto-injector into the carrier tube, if possible, and throw away (dispose of) it properly as directed. See the Instructions for Use for detailed information on how to safely handle and throw away (dispose of) the used auto-injector. Epinephrine Injection is packaged in a carton containing 2 Epinephrine Injections auto-injectors, each in an individual carrier tube. Do not drop the carrier tube or Epinephrine Injection. If the carrier tube or Epinephrine Injection is dropped, check for damage or leakage. Throw away (dispose of) and replace Epinephrine Injection if damage or leakage is noticed or suspected. You may request a separate Trainer at www.epinephrineautoinject.com. The epinephrine injection Trainer has a beige color. The beige epinephrine injection Trainer contains no medicine and no needle. Practice using the Trainer before an allergic emergency occurs so you know how to use Epinephrine Injection correctly. Always carry your real Epinephrine Injection, USP auto-injector with you in case of an allergic emergency. What are the possible side effects of Epinephrine Injection? Epinephrine Injection may cause serious side effects. Injection-related complications Epinephrine Injection should only be injected into the middle of your outer thigh (upper leg). Do not inject Epinephrine Injection into a vein, buttocks, fingers, toes, hands, or feet. If you accidentally inject Epinephrine Injection into any other part of your body, administer a second dose of Epinephrine Injection into the middle of the outer thigh (upper leg) and go to the nearest emergency room right away. Tell the healthcare provider where on your body the injection occurred. Serious infections at the injection site Rarely, people who have used Epinephrine Injection may develop serious skin and soft tissue infections at the injection site within a few days after injection. Call your healthcare provider right away if you notice any of the following at the injection site: o redness that does not go away o swelling o tenderness o warmth at the injection site Other side effects If you have certain medical conditions, or take certain medicines, your condition may get worse or you may have more or longer lasting side effects when you use Epinephrine Injection. Talk to your healthcare provider about all of your medical conditions. Common side effects of Epinephrine Injection include: fast, irregular or “pounding” heartbeat sweating headache weakness shakiness paleness feelings of excitement, nervousness or anxiety dizziness ·nausea or vomiting breathing problems These side effects may go away with rest. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Epinephrine Injection. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Amneal Pharmaceuticals LLC at 1-877-835-5472. How should I store Epinephrine Injection? Store Epinephrine Injection at room temperature between 68°F to 77°F (20°C to 25°C). Keep Epinephrine Injection in the individual carrier tube provided to protect it from light and damage. The carrier tube is not waterproof. Do not expose Epinephrine Injection to extreme heat or cold. For example, do not store in your vehicle’s glove box and do not store it in the refrigerator or freezer. Periodically examine the solution through the viewing window of your Epinephrine Injection. The solution should be clear and colorless . Replace Epinephrine Injectionif the solution appears discolored (pinkish or brown), cloudy, or contains particles. The blue needle shield cap and blue end cap helps to prevent accidental injection. Do not remove the blue needle shield cap or blue end caps until you are ready to use Epinephrine Injection. After the auto-injector is used, throw away the blue end caps immediately, as they may pose a choking hazard for young children. Keep Epinephrine Injection and all medicines out of the reach of children. Disposing of an Expired, Unused or Used Epinephrine Injection Your Epinephrine Injection has an expiration date. Replace it before the expiration date. Throw away (dispose of) expired, unwanted, or unused Epinephrine Injections in an FDA-cleared sharps disposal container. Do not throw away Epinephrine Injection in your household trash. If you do not have an FDA-cleared sharps disposal container, you may use a household container that is: Made of heavy-duty plastic, Can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, Upright and stable during use, Leak-resistant, and Properly labeled to warn of hazardous waste inside the container. When your sharps disposal container is almost full, follow your community guidelines for proper disposal. There may be state or local laws about how you should dispose of used needles and syringes. For more information about safe sharps disposal, visit the FDA website at www.fda.gov/safesharpsdisposal . General information about the safe and effective use of Epinephrine Injection: Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Epinephrine Injection for a condition for which it was not prescribed. Do not give Epinephrine Injection to other people. This Patient Information leaflet summarizes the most important information about Epinephrine Injection. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for information about Epinephrine Injection that is written for health professionals. For more information and video instructions on the use of Epinephrine Injection, go to www.epinephrineautoinject.com or call 1-877-835-5472. What are the ingredients in Epinephrine Injection? Active Ingredient: epinephrine Inactive Ingredients: sodium chloride, chlorobutanol, sodium bisulfite, hydrochloric acid, sodium hydroxide, and water. Important Information The Epinephrine Injection, 0.3 mg auto-injector has a yellow-colored label. The Epinephrine Injection, 0.15 mg auto-injector has an orange-colored label. The Epinephrine Injection Trainer has a beige color, and contains no medicine and no needle. Your Epinephrine Injection is designed to work through clothing. The blue needle shield cap and the blue end cap on Epinephrine Injection help to prevent accidental injection of the device. Do not remove the blue needle shield cap and blue end caps until you are ready to use it. Choking hazard: The blue needle shield cap and blue end caps are small parts that may become a choking hazard for children. Throw away the blue end caps immediately after use. Only inject into the middle of the outer thigh (upper leg). Never inject into any other part of the body. Never put your thumb, fingers, or your hand over the red needle end. The needle comes out of the red needle end. If an accidental injection happens, get medical help right away. Do not place patient information or any other foreign objects in carrier with the auto-injector, as this may prevent you from removing Epinephrine Injection for use. Incorrect Use and Correct Use of Epinephrine Injection Incorrect Use Correct Use and Important Reminders Storing Epinephrine Injection outside the carrier tube. Always keep Epinephrine Injection stored in the individual carrier tube provided to protect it from light and damage. The carrier tube is not waterproof. Storing of the Epinephrine Injection outside of the recommended storage conditions. Always keep your Epinephrine Injection stored at room temperature (68°F to 77°F / 20°C to 25°C). Failing to remove the Epinephrine Injection from the carrier tube before use. Remove Epinephrine Injection from the carrier tube before use. Failing to remove both the blue caps in proper sequence before use. Before use, remove the blue needle shield cap first to expose the red needle end. Then remove the blue end cap. Failing to remove both blue caps before use. Epinephrine Injection will not activate or deliver the dose if both blue caps are not removed. Failing to remove the blue caps in the proper order. Removing the blue caps in the incorrect order may cause premature activation of Epinephrine Injection. Failing to remove the blue needle shield cap properly, resulting in the needle sheath remaining in place. Pull off the blue needle shield cap by grasping the ribbed area and pulling straight off until the red needle end is visible. Do not squeeze the non-ribbed area. Activating Epinephrine Injection upside down, resulting in injection into the hand. The needle exits from the red needle end, which must be placed against the middle of the outer thigh (upper leg) at a 90˚ angle (perpendicular) before and during activation. Failing to apply enough force to activate Epinephrine Injection. Press down hard and hold Epinephrine Injection firmly against the outer thigh at a 90˚ angle for 10 seconds. Do not swing or jab the device. Expecting an audible click to confirm activation. You may or may not hear a sound when the injection starts. Assuming the dose was not delivered because liquid remains in the device. It is normal for most of the medicine to remain in the auto-injector after the dose is delivered. The dose has been delivered if the needle is visible after use. Administering at an injection site other than the outer thigh. Inject Epinephrine Injection only into the middle of the outer thigh (upper leg). Removing the device at an angle, causing needle bending. Place the red needle end against the thigh at a 90° angle (perpendicular), press down firmly, and remove the device straight out at a 90° angle after injection. Failing to hold Epinephrine Injection in place long enough. Hold Epinephrine Injection firmly in place for a full 10 seconds to ensure dose delivery. Failing to locate the expiration date. Remove Epinephrine Injection from the carrier tube. The expiration date is located on the auto-injector label. For more information and video instructions on the use of Epinephrine Injection, go to www.epinephrineautoinject.com or call 1-877-835-5472. This Patient Information has been approved by the U.S. Food and Drug Administration Rev. 03/2026
Table text from source:
| PATIENT INFORMATIONEPINEPHRINE injection (ep″ i nef′ rin),for intramuscular or subcutaneous useEpinephrine Injection USP, 0.3 mgEach Epinephrine Injection USP, 0.3 mg delivers a single dose of 0.3 mg epinephrine USP, in 0.3 mL (0.3 mg/0.3 mL)Epinephrine Injection USP, 0.15 mg Each Epinephrine Injection USP, 0.15 mg delivers a single dose of 0.15 mg epinephrine USP, in 0.15 mL (0.15 mg/0.15 mL)For allergic emergencies (anaphylaxis)
| Read this Patient Information leaflet carefully before you use Epinephrine Injection and each time you get a refill. There may be new information. You, your parent, caregiver, or others who may be able to administer Epinephrine Injection should know how to use it before you have an allergic emergency. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.
| What is the most important information I should know aboutEpinephrine Injection? 1. Epinephrine Injection is a medicine used to treat allergic emergencies (anaphylaxis). Anaphylaxis can be life-threatening and can happen within minutes. If untreated, anaphylaxis can lead to death. Allergic emergencies may be caused by stinging and biting insects, allergy injections, foods, medicines, exercise, or other unknown causes. Symptoms of anaphylaxis may include:trouble breathingwheezinghoarseness (changes in the way your voicesounds)hives (raised reddened rash that may itch)severe itchingswelling of your face, lips, mouth, or tongueskin rash, redness, or swellingfast heartbeatweak pulsefeeling very anxiousconfusionstomach painlosing control of urine or bowel movements (incontinence)diarrhea or stomach crampsdizziness, fainting, or “passing out” (unconsciousness)2. It is recommended that people are prescribed and have immediate access to 2 Epinephrine Injection devices at all times. Sometimes a single dose of epinephrine may not be enough to treat a serious allergic reaction before seeking emergency medical help. You should also have immediate access to 2 Epinephrine Injection devices in case the first device is activated before the dose can be given. A device that has been activated accidentally cannot be used to treat an allergic emergency (anaphylaxis).Note: Epinephrine Injection has been activated if you see the needle sticking out of the red needle end and the viewing window is blocked.You may not know when an allergic emergency (anaphylaxis) will happen.Talk to your healthcare provider if you need additional Epinephrine Injection devices to keep at work, school, or other locations. If you use 1 Epinephrine Injection device to treat an emergency allergic reaction, be sure to replace it so you always have immediate access to 2 devices. Tell your family members, caregivers, and others where you keep your Epinephrine Injection. Make sure they know how to use it before you need it. You may be unable to speak in an allergic emergency. 3. When you have an allergic emergency (anaphylaxis) use Epinephrine Injection right away. Get emergency medical help for further treatment of the allergic emergency (anaphylaxis), if needed, after using Epinephrine Injection. Before you receive Epinephrine Injection, your healthcare provider should talk to you about when to get emergency help. If symptoms do not improve or if they worsen after the first dose, or you accidentally inject Epinephrine Injection intothe fingers, toes, hands or feet, a second dose of Epinephrine Injection may be administered with a second auto-injector starting 5 minutes after the first dose. If more than 2 doses are needed for an allergic emergency, they must be given by a healthcare provider.
| What isEpinephrine Injection? Epinephrine Injection is a medicine used to treat life-threatening allergic emergencies (anaphylaxis). It is delivered using a disposable, prefilled automatic injection device (auto-injector). Each auto-injector contains a single dose of epinephrine. Epinephrine Injection is for immediate administration by you or your caregiver. Get emergency medical help, if needed, after using Epinephrine Injection. Your healthcare provider should talk to you about when to get emergency help.Epinephrine Injection is for people who have been prescribed this medicine by their healthcare provider. The Epinephrine Injection 0.3 mg auto-injector is for people who weigh 66 pounds or greater. The Epinephrine Injection 0.15 mg auto-injector is for people who weigh 33 pounds to less than 66 pounds. It is not known if Epinephrine Injection is safe and effective in children who weigh less than 33 pounds.
| What should I tell my healthcare provider before using Epinephrine Injection?Before you use Epinephrine Injection, tell your healthcare provider about all your medical conditions. Your healthcare provider may give you more instructions about when and how to use your Epinephrine Injection if you have the following: heart problems or high blood pressure diabetes thyroid problems asthma a history of depression Parkinson’s disease kidney (renal) problems You may also receive more instructions if you:are pregnant or plan to become pregnant. It is not known if epinephrine will harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if epinephrine passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Also tell your healthcare provider about all known allergies. Some medicines may increase or decrease the effects of epinephrine, and epinephrine may affect how other medicines work. Know the medicines you take. Keep a list of all your medicines, including over-the-counter medicines, vitamins and herbal supplements to show your healthcare provider and pharmacist when you get a new medicine. Use your Epinephrine Injection for treatment of anaphylaxis as prescribed by your healthcare provider, regardless of your medical conditions or the medicine you take.
| How should I useEpinephrine Injection? Use your single-dose Epinephrine Injection exactly as your healthcare provider tells you to use it.When you have an allergic emergency (anaphylaxis), use Epinephrine Injection right away. Get emergency medical help, if needed, after using Epinephrine Injection.You may need to use a second Epinephrine Injection if symptoms continue or come back after the first dose. A second dose may be administered starting 5 minutes after the first dose while you wait for emergency medical help, or if the first Epinephrine Injection is activated before the dose can be given. If you need more than 2 doses of epinephrine for a single anaphylaxis episode, additional doses must be given by a healthcare provider. Epinephrine Injection should only be injected into the middle of the outer thigh (upper leg). It can be injected through clothing if needed. Do not inject into a vein, buttocks, fingers, toes, hands or feet.If Epinephrine Injection is injected into the fingers, toes, hands or feet, administer a second dose of Epinephrine Injection into the middle of the outer thigh (upper leg). If symptoms worsen or persist, go immediately to the nearest emergency room for further treatment of anaphylaxis.Read and make sure you understand the Instructions for Use for information about the correct way to use Epinephrine Injection. Your healthcare provider will show you how to safely use Epinephrine Injection. It is very important that you hold Epinephrine Injection firmly against the middle of the outer thigh (upper leg) for a full 10 seconds. If you do not hold it in place long enough, Epinephrine Injection may not deliver the full dose of medicine.Caution: Never put your thumb, fingers, or hand over the red needle end. Never press or push the red needle end with your thumb, fingers, or hand.The needle comes out of the red needle end. Accidental injection into the fingers, hands, or feet may cause a loss of blood flow to those areas. If this happens, give a second dose of Epinephrine Injection into the middle of the outer thigh (upper leg) and go immediately to the nearest emergency room. Tell the healthcare provider where on your body the injection occurred. Warning: After the device is activated, the needle does not retract back into the device. After use, carefully place the used auto-injector into the carrier tube, if possible, and throw away (dispose of) it properly as directed.See the Instructions for Use for detailed information on how to safely handle and throw away (dispose of) the used auto-injector.Epinephrine Injection is packaged in a carton containing 2 Epinephrine Injections auto-injectors, each in an individual carrier tube.Do not drop the carrier tube or Epinephrine Injection. If the carrier tube or Epinephrine Injection is dropped, check for damage or leakage. Throw away (dispose of) and replace Epinephrine Injection if damage or leakage is noticed or suspected.You may request a separate Trainer at www.epinephrineautoinject.com. The epinephrine injection Trainer has a beige color. The beige epinephrine injection Trainer contains no medicine and no needle. Practice using the Trainer before an allergic emergency occurs so you know how to use Epinephrine Injection correctly. Always carry your real Epinephrine Injection, USP auto-injector with you in case of an allergic emergency.
| What are the possible side effects ofEpinephrine Injection? Epinephrine Injection may cause serious side effects. Injection-related complicationsEpinephrine Injection should only be injected into the middle of your outer thigh (upper leg). Do not inject Epinephrine Injection into a vein, buttocks, fingers, toes, hands, or feet. If you accidentally inject Epinephrine Injection into any other part of your body, administer a second dose of Epinephrine Injection into the middle of the outer thigh (upper leg) and go to the nearest emergency room right away. Tell the healthcare provider where on your body the injection occurred. Serious infections at the injection siteRarely, people who have used Epinephrine Injection may develop serious skin and soft tissue infections at the injection site within a few days after injection. Call your healthcare provider right away if you notice any of the following at the injection site: o redness that does not go awayo swellingo tendernesso warmth at the injection siteOther side effectsIf you have certain medical conditions, or take certain medicines, your condition may get worse or you may have more or longer lasting side effects when you use Epinephrine Injection. Talk to your healthcare provider about all of your medical conditions. Common side effects of Epinephrine Injection include:fast, irregular or “pounding” heartbeatsweatingheadacheweaknessshakinesspalenessfeelings of excitement, nervousness or anxietydizziness·nausea or vomitingbreathing problemsThese side effects may go away with rest. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Epinephrine Injection. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Amneal Pharmaceuticals LLC at 1-877-835-5472.
| How should I storeEpinephrine Injection? Store Epinephrine Injection at room temperature between 68°F to 77°F (20°C to 25°C).Keep Epinephrine Injection in the individual carrier tube provided to protect it from light and damage. The carrier tube is not waterproof.Do not expose Epinephrine Injection to extreme heat or cold. For example, do not store in your vehicle’s glove box and do not store it in the refrigerator or freezer. Periodically examine the solution through the viewing window of your Epinephrine Injection. The solution should be clear and colorless. Replace Epinephrine Injectionif the solution appears discolored (pinkish or brown), cloudy, or contains particles.The blue needle shield cap and blue end cap helps to prevent accidental injection. Do not remove the blue needle shield cap or blue end caps until you are ready to use Epinephrine Injection. After the auto-injector is used, throw away the blue end caps immediately, as they may pose a choking hazard for young children.Keep Epinephrine Injection and all medicines out of the reach of children.Disposing of an Expired, Unused or Used Epinephrine InjectionYour Epinephrine Injection has an expiration date. Replace it before the expiration date.Throw away (dispose of) expired, unwanted, or unused Epinephrine Injections in an FDA-cleared sharps disposal container. Do not throw away Epinephrine Injection in your household trash. If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:Made of heavy-duty plastic,Can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,Upright and stable during use,Leak-resistant, andProperly labeled to warn of hazardous waste inside the container.When your sharps disposal container is almost full, follow your community guidelines for proper disposal. There may be state or local laws about how you should dispose of used needles and syringes. For more information about safe sharps disposal, visit the FDA website at www.fda.gov/safesharpsdisposal.
| General information about the safe and effective use of Epinephrine Injection:Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Epinephrine Injection for a condition for which it was not prescribed. Do not give Epinephrine Injection to other people. This Patient Information leaflet summarizes the most important information about Epinephrine Injection. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for information about Epinephrine Injection that is written for health professionals. For more information and video instructions on the use of Epinephrine Injection, go to www.epinephrineautoinject.com or call 1-877-835-5472.
| What are the ingredients inEpinephrine Injection?Active Ingredient: epinephrine Inactive Ingredients: sodium chloride, chlorobutanol, sodium bisulfite, hydrochloric acid, sodium hydroxide, and water.
| Important Information TheEpinephrine Injection, 0.3 mg auto-injector has a yellow-colored label. The Epinephrine Injection, 0.15 mg auto-injector has an orange-colored label. The Epinephrine Injection Trainer has a beige color, and contains no medicine and no needle. Your Epinephrine Injection is designed to work through clothing. The blue needle shield cap and the blue end cap on Epinephrine Injection help to prevent accidental injection of the device. Do not remove the blue needle shield cap and blue end caps until you are ready to use it. Choking hazard: The blue needle shield cap and blueend caps are small parts that may become a choking hazard for children. Throw away the blue end caps immediately after use.Only inject into the middle of the outer thigh (upper leg). Never inject into any other part of the body. Never put your thumb, fingers, or your hand over the red needle end. The needle comes out of the red needle end. If an accidental injection happens, get medical help right away. Do not place patient information or any other foreign objects in carrier with the auto-injector, as this may prevent you from removing Epinephrine Injection for use.
| Incorrect Use | Correct Use and Important Reminders
| Storing Epinephrine Injection outside the carrier tube. | Always keep Epinephrine Injection stored in the individual carrier tube provided to protect it from light and damage. The carrier tube is not waterproof.
| Storing of the Epinephrine Injection outside of the recommended storage conditions. | Always keep your Epinephrine Injection stored at room temperature (68°F to 77°F / 20°C to 25°C).
| Failing to remove the Epinephrine Injection from the carrier tube before use. | Remove Epinephrine Injection from the carrier tube before use.
| Failing to remove both the blue caps in proper sequence before use. | Before use, remove the blue needle shield cap first to expose the red needle end. Then remove the blue end cap.
| Failing to remove both blue caps before use. | Epinephrine Injection will not activate or deliver the dose if both blue caps are not removed.
| Failing to remove the blue caps in the proper order. | Removing the blue caps in the incorrect order may cause premature activation of Epinephrine Injection.
| Failing to remove the blue needle shield cap properly, resulting in the needle sheath remaining in place. | Pull off the blue needle shield cap by grasping the ribbed area and pulling straight off until the red needle end is visible. Do not squeeze the non-ribbed area.
| Activating Epinephrine Injection upside down, resulting in injection into the hand. | The needle exits from the red needle end, which must be placed against the middle of the outer thigh (upper leg) at a 90˚ angle (perpendicular) before and during activation.
| Failing to apply enough force to activate Epinephrine Injection. | Press down hard and hold Epinephrine Injection firmly against the outer thigh at a 90˚ angle for 10 seconds. Do not swing or jab the device.
| Expecting an audible click to confirm activation. | You may or may not hear a sound when the injection starts.
| Assuming the dose was not delivered because liquid remains in the device. | It is normal for most of the medicine to remain in the auto-injector after the dose is delivered. The dose has been delivered if the needle is visible after use.
| Administering at an injection site other than the outer thigh. | Inject Epinephrine Injection only into the middle of the outer thigh (upper leg).
| Removing the device at an angle, causing needle bending. | Place the red needle end against the thigh at a 90° angle (perpendicular), press down firmly, and remove the device straight out at a 90° angle after injection.
| Failing to hold Epinephrine Injection in place long enough. | Hold Epinephrine Injection firmly in place for a full 10 seconds to ensure dose delivery.
| Failing to locate the expiration date. | Remove Epinephrine Injection from the carrier tube. The expiration date is located on the auto-injector label.
The text is extracted from a US structured product label. Tables are represented as text where supplied; formatting and illustrations may be lost. A missing section does not mean a risk is absent. This reference has not been independently reviewed by a clinician and is not a live safety-alert service.